Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozone therapy for chemotherapy-induced peripheral neuropathic pain
2024-518021-16-00Phase 3Authorised
- Sponsor
- Dr. Bernardino Clavo Varas
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) and Neuralgia comparing Ozone therapy with Oxygen placebo (2 arms). Primary endpoints: Average pain level according to the Brief Pain Inventory-Short Form (BPI-SF) and Direct hospital costs. Planned start Sep 2024; status: authorised.
02
Drugs
medical ozonated water
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)Neuralgia
Beyond the preview
Go deeper on 2024-518021-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518021-16-00.